# EDGAR Filing Document

**Accession Number:** 0000943819
**File Stem:** 0001193125-23-085659
**Filing Date:** 2023-3
**Character Count:** 10194
**Document Hash:** 75c4cde2a4e99d3402a32edc4127b146
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-085659.hdr.sgml**: 20230330

**ACCESSION NUMBER**: 0001193125-23-085659

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230329

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230330

**DATE AS OF CHANGE**: 20230330

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RESMED INC
- **CENTRAL INDEX KEY:** 0000943819
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 980152841
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15317
- **FILM NUMBER:** 23781223

**BUSINESS ADDRESS:**
- **STREET 1:** 9001 SPECTRUM CENTER BLVD.
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92123
- **BUSINESS PHONE:** 8587462400

**MAIL ADDRESS:**
- **STREET 1:** 9001 SPECTRUM CENTER BLVD.
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92123

?xml version="1.0" encoding="utf-8" ? 8-K

------

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### Under Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported):

#### March 29, 2023

------

## ResMed Inc.

#### (Exact Name of Registrant as Specified in Charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-15317** | **98-0152841** |
| **(State or Other Jurisdiction of**<br> **Incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

---

| |
|:---|
| **9001 Spectrum Center Blvd.** |
| **San Diego, California 92123** |
| **(Address of Principal Executive Offices)** |

---

(858) 836-5000

#### (Registrant's telephone number, including area code)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common Stock, $0.004 par value | RMD | NYSE |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

------

---

| | |
|:---|:---|
| **Item 5.02.** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**  |

---

On March 29, 2023, David Pendarvis, our global general counsel, chief administrative officer, and secretary, notified us that he intends to retire, effective June 30, 2023. Mr. Pendarvis has served as an executive officer of ResMed for over 20 years and intends to retire after a 39-year career in law and business. In accordance with ResMed's ongoing executive officer succession planning process, we have initiated an internal candidate search to identify Mr. Pendarvis' successor and ensure a smooth transition.

Until the effective date of his retirement, Mr. Pendarvis will continue to receive his current salary, benefits, and vesting of long-term equity incentives. In connection with the retirement, we have agreed that Mr. Pendarvis will remain eligible for a short-term incentive cash payment for fiscal year 2023, on the same basis as similarly situated executives, based on his continued employment through June 30, 2023 even though he will not be employed on the date of the payment.

From July 1, 2023, through December 31, 2023, Mr. Pendarvis will serve as a consultant to us, to assist with the transition of his former duties. We have agreed to compensate him for these consulting services at a rate of $10,000 per month. In addition, he will remain eligible for continued vesting of outstanding equity awards, during the consulting period, in accordance with the terms of our equity incentive plans, and the specific equity grants previously made to him.

#### Item 9.01. Financial Statements and Exhibits.
(d) Exhibits

---

| | |
|:---|:---|
| Exhibits: | Description of Document |
| 99.1 | [Press Release dated March 30, 2023](d447060dex991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL, document) |

---

------

#### SIGNATURES
We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

---

| | | |
|:---|:---|:---|
| Date: March 30, 2023 | **RESMED INC.** | **RESMED INC.** |
|  | (registrant) | (registrant) |
|  | By: | /s/ Brett Sandercock |
|  | Name: Brett Sandercock | Name: Brett Sandercock |
|  | Its: Chief financial officer | Its: Chief financial officer |

---

## Exhibit 99.1

**Exhibit 99.1**![LOGO](g447060g0330203856225.jpg)

---

| | |
|:---|:---|
| **For media** | **For investors** |
| <u>news@resmed.com</u> | <u>investorrelations@resmed.com</u> |
| +1 858.836.6798 | +1 858.836.5000 |

---

**ResMed Chief Administrative Officer and Global General Counsel to Retire** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *ResMed to conduct an internal search for a successor general counsel* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Amy Wakeham appointed Chief Communications and Investor Relations Officer, will join ResMed's executive leadership team* 

SAN DIEGO, March 30, 2023 – ResMed (NYSE: RMD, ASX: RMD) announced today that David Pendarvis, chief administrative officer, global general counsel, and secretary, plans to retire, effective June 30, 2023. He will remain in a consulting role with ResMed through December 31, 2023.

ResMed will conduct an internal search for the successor to Pendarvis' legal roles and expects to name a new global general counsel and secretary well ahead of David's retirement date to ensure a smooth and seamless transition. Amy Wakeham, ResMed's current Vice President of Corporate Communications & Investor Relations, has been appointed Chief Communications and Investor Relations Officer to succeed Pendarvis in his role leading corporate public affairs; she will report to the Office of the CEO and will join ResMed's executive leadership team, effective April 1, 2023.

"Dave has been an integral part of ResMed for over 20 years, helping guide the company into and through its transformation from the pioneer of sleep apnea treatment to a $30 billion-plus global leader in digital health and cloud-connected medical devices," said CEO Mick Farrell. "On behalf of the entire management team and the board, I want to thank Dave for his two decades of dedicated service and exemplary leadership that has helped build the industry-leading company that ResMed is today. He's been an important leader in an executive team that has positioned ResMed to improve the lives of many millions of people living with chronic respiratory diseases and countless more seeking to age healthily and outside the hospital. Personally, Dave has been a trusted advisor, partner, friend, and mentor to me through the years, I will miss his guidance, insights, and quick sense of humor."

"My best wishes to Dave on a much-deserved retirement, and congratulations to Amy on her well-earned appointment," Farrell said. "Through an internal search process, we will identify a well-qualified successor for the global general counsel role ahead of Dave's retirement to ensure a smooth transition into these critical roles. This speaks to the overall depth of ResMed's leadership bench strength and broad expertise across our global team of over 10,000 ResMedians as we continue to execute our strategy that will help 250 million people sleep, breathe, and live healthier lives in 2025."

------

---

| | |
|:---|:---|
| *RMD CAO and Global General Counsel to Retire – March 30, 2023* | *Page* ***2*** *of* ***2*** |

---

Pendarvis, age 64, retires after a nearly 40-year career in law and business. He joined ResMed in 2002, following private practice as a partner with the firms of Gibson Dunn and Gray Cary Ware & Freidenrich (now DLA Piper). He has had several roles at ResMed: global general counsel, secretary, senior vice president of organizational development, chief administrative officer, and interim president – Europe, Middle East, Africa, and Japan.

**About ResMed** 

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies" and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit <u>ResMed.com</u> and follow @ResMed.

# # #